Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.

Abstract

OBJECTIVE:

The purpose of this study was to evaluate the activity of ifosfamide (isophosphamide) in patients with advanced or recurrent leiomyosarcoma not previously exposed to chemotherapy.

STUDY DESIGN:

This is a phase II groupwide study of the Gynecologic Oncology Group. Thirty-five patients were treated with ifosfamide 1.5 gm/m2 daily intravenously for 5 days with mesna (mercaptoethane sodium sulfonate). Fifty-six patients had received prior abdominal hysterectomy and 15 prior radiotherapy. The dose was reduced to 1.2 gm/m2 daily in patients who had received prior radiotherapy.

RESULTS:

Gynecologic Oncology Group grade III or IV granulocytopenia occurred in 4 (11%) patients, and none had grade IV thrombocytopenia. One (2.8%) patient had grade IV neurotoxicity. Partial responses were observed in 6 of 35 (17.2%) patients. The 95% confidence interval for response was 6.6% to 33.7%.

CONCLUSION:

These results indicate that ifosfamide has modest activity in patients with advanced or recurrent leiomyosarcomas of the uterus.

• Authors: G P Sutton, J A Blessing, R J Barrett, R McGehee
• Journal: American journal of obstetrics and gynecology (Am J Obstet Gynecol) Vol. 166 Issue 2 Pg. 556-9 (Feb 1992) ISSN: 0002-9378 [Print] United States
• PMID: 1536229 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Mesna
• Ifosfamide

Topics

• Adult
• Aged
• Agranulocytosis (chemically induced)
• Drug Evaluation
• Drug Therapy, Combination
• Female
• Humans
• Ifosfamide (adverse effects, therapeutic use)
• Leiomyosarcoma (drug therapy)
• Mesna (therapeutic use)
• Middle Aged
• Remission Induction
• Uterine Neoplasms (drug therapy)